Hong, Jau-Shyong
Professor & Head, NIH/NIEHS
Honors and Award:
Comprehensive Oral for the Doctorate: Honors, 1972
Research Award, University of Kansas, 1972
Final Oral Examination for the Doctorate: Honors, 1973
NIH Individual Research Fellowship Award, 1975-1977
Distinguished Alumnus Award, School of Medicine, University of
Kansas, 1982
Session Chairman, International Union of Pharmacology Meeting,
London, England, 1984
Session Chairman, International Meeting of Toxicology, Symposium
on "NeuralMembranes as a Target of Toxicity", Kuopio, Finland,
1985
Session Chairman, ASPET Symposium, Boston, MA, 1986
Ad Hoc Reviewer, NIDA/NIH, 1986
Ad Hoc Reviewer, NIDA/NIH, 1987
Session Chairman, Winter Brain Conference, Aspen, CO, 1988
NIH Outstanding Performance Award, 1988
Session Chairman, International Symposium on Neurotransmission
and Signal Transmission, Taipei, Taiwan, 1989
NIH Outstanding Performance Award, 1989
Advisor, National Research Council, Research Associateship
Program, 1989-Present
Preceptor, Pharmacology Research Associate Program, NIGMS/NIH,
1989-Present
NIH Outstanding Performance Award, 1990
NIH Outstanding Performance Award, 1991
Session Chairman, 7th International Catecholamine Symposium,
Amsterdam, The Netherlands, 1992
NIH Outstanding Performance Award, 1992
Honorary Speaker for Lo Yuk Tong Foundation Lecture, University
of Hong Kong, 1992
Honorary Professor, Shanghai Medical University, China, 1992
Member Review Committee, Shanghai Medical University, 1992 Present Session Chairman, The Fifth SCBA Symposium, Baltimore,
MD, 1993
NIH Outstanding Performance Award, 1993
NIEHS/NIH AIDS Research Awards, 1994 - 1996
Member Review Committee, National Science Council, Taiwan,
1994
NIEHS/NIH AIDS Research Award, 1995-1997
NIEHS/NIH EMF Research Award, 1995-1997
NIEHS/NIH AIDS Research Award, 1997-1999
Keynote Speaker for the International Conference Commemorating
the 50th Anniversary of the Korean Society of Pharmacology, 1997
Session Chairman, Satellite Symposium, Neuroscience Society
Meeting, FL, 1999
Session Chairman, Satellite Symposium, Neuroscience Society
Meeting, LA, 2000
Keynote Speaker, Frontiers in Neuroscience, Taiwan, 2002.
NIEHS/NIH, Intramural Research Award 2000-2003
NIEHS/NIH, AIDS Research Award, 2003-2006
NIEHS/NIH, Mentor of the Year Award 2003
Foreign Advisor for National Health Research Institute, Taiwan,
2003-Present
Keynote Speaker, Asian-Pacific Physiological Society Meeting, 2004
Consultant for Amgen Company, Thousand Island, CA. 2004
Session Chairman on “Neurodegeneration and Neuroprotection”,
Symposium on Inflammation-related Neurodegeneration, Taiwan,
2004
Session Chair on “Seventh International Conference on Neuroprotective
Agents”, Monterey, California”, 2004.
Keynote Speaker, Annual Meeting of Chinese Neuropharmacology
Society, Zunyi, China 2006.
Keynote Speaker, Symposium on Recent Advance in New Drug
Development, Taiwan, 2008.
Keynote Speaker, Helsinki Drug Research Conferences, 2008, Helsinki,
Finland.
Societies:
American Society of Pharmacology and Experimental Therapeutics
Society for Neuroscience
International Narcotic Research Club
Society of Immunopharmacology
Editorial Board:
Neurotoxicology (1986 - 1992)
Neuropharmacology (1987 - 1992)
Environmental Health Perspectives (1988 - 1997)
Molecular and Cellular Neuroscience (1990 - 1994)
Biological Signals (1990 - 2000)
Journal of Biomedicine & Biotechnology (2000-Present)
Journal of Nonlinearity in Biology, Toxicology and Medicine
(2002-Present)
Research Summary
Recent studies suggest important roles for glial cells-astroglia and
microglia-in the development, differentiation and survival of neurons in
the brain. Both astroglia and microglia become activated in response to
brain injury, a process termed "reactive gliosis." However, these two
kinds of activated glial cells exert very different effects on the
neighboring neurons. Microglia, which are the predominant cell type in
the central nervous system that express the major histocompatibility
complex class II molecule, play an important role in immune surveillance.
However, during reactive gliosis, microglia secrete neurotoxic substances,
such as excitatory amino acids, proinflammatory cytokines or free
radicals, which kill neurons and have been proposed to be the major
causes of neurodegenerative diseases, such as Alzheimer's disease and
Parkinson's disease. Because neurodegeneration is a common sequela for
patients exposed to a variety of environment-related neurotoxins,
information generated from this line of research should further the
Neuropharmacology Group’s understanding of the mechanisms of action
for neurotoxicants.
Invited Speaker in Symposiums or Meetings:
Symposium on "Endorphins in Mental Health Research", Puerto
Rico, 1977. "Participation of (Met5)-Enkephalin in the Action of
Antipsychotic Drugs",
American College of Neuropsychopharmacology Meeting, Puerto
Rico, 1977. "Participation of Substance P in the Action of
Haloperidol,"
11th College of International Neuropsychopharmacology Congress,
Vienna, Austria, 1978. “Enkephalin and Antipsychotic Medication,"
Symposium on "Long Term Effects of Neuroleptics," Monte-Carlo,
1979. "Effects of Long Term Administration of Antipsychotic Drugs
on Enkephalinergic Neuron,"
Symposium on "Neuropeptides and Neuronal Communication,"
Bresia, Italy, 1979. "Recurrent Convulsions and Hippocampal
(Met5)-Enkephalin Content,"
Satellite Symposium to the 8th International Congress of
Pharmacology, Gifu, Japan, 1981. "Effects of Administration of
Psychoactive Drugs on Brain Neuropeptide Systems,"
Conference on Dynamics of Neurotransmitter Function, Washington,
D.C., October 24-26, 1981. "Hormonal Regulation of Pituitary
Endorphin Systems,"
Neurotoxicology of Selected Chemicals Conference, Chicago, IL,
1982. "Effects of Chlordecone Administration on Brain
Neuropeptide Systems,"
Symposium on "Chemical Modulations of Regulatory Peptides"
FASEB Meeting, St. Louis, MO, 1984. "Chemical Modulation of
Brain Enkephalins by Antipsychotic Drugs"
International Conference on the Neurotoxicology of Selective
Chemicals, Little Rock, AR, 1984. "Chlordecone Alters
Hypothalamo-Pituitary-Adrenal Function in Adult Rats"
Symposium on "Neural Membranes as a Target of Toxicity," Kuopio,
Finland, 1985. "Possible Role of the Sodium Channel in the
Neurotoxicity of Organochlorine Insecticides In Vivo in Rats,"
ASPET Meeting, St. Louis, MO, 1985. "Estrogenic Effects of
Chlordecone and Neuroendocrine Function," Symposium on "The
Use of Organochlorine Insecticides in Neurobiology,"
Workshop on "The Recent Advances in Neuropharmacology," Taipei,
Taiwan, 1985. "Modulation of Brain Opioid Peptides by
Antipsychotic Drugs and Electroconvulsive Shock,"
ASPET Symposium, Boston, MA, 1986. "The Use of Cytotoxicants
to Study Metabolism of Opiate Peptides in the Hippocampus,"
Society of Neuroscience Symposium, Washington, D.C.,
1986. "Seizure-Induced Alterations in the Metabolism of Opioid
Peptides in Identified Pathways of the Hippocampus,"
ACNP Symposium, 1987. "Dopaminergic Regulation of Gene
Expression of Opioid Peptides and Tachykinins in the Basal
Ganglia,"
Workshop on "Recent Advances in Neurobiology," Taipei, Taiwan,
1987. "Regulation of Gene Expression of Brain Neuropeptides by
Transmitter Systems,"
Winter Brain Conference, Aspen, CO, 1988. "Roles of Hippocampal
Opioid Peptides in Seizures,"
International Symposium on Neurotransmission and Signal
Transmission, Taipei, Taiwan, 1989. "Long-Term Regulation of
Expression of Proenkephalin and Catecholamine Synthetic Enzymes
in the Adrenal Medulla,"
Winter Conference on Brain Research, Snow Mass, CO, 1990.
"Regulation of Dynorphin Gene Expression by Excitatory Amino
Acids in Rat Hippocampus,"
International Symposium on the Dentate Gyrus and Its Role in
Seizures, Irvine, CA, 1991. "Regulation of Opioid Peptide Gene
Expression in the Dentate Gyrus,"
International Symposium on Neuropeptides in Endocrine and
Autonomic Regulation, Taipei, Taiwan, 1992. "Roles of Signal
Transduction Pathway on the Regulation of Opioid Peptide Gene
Regulation,"
7th International Catecholamine Symposium, Amsterdam, The
Netherlands, 1992. "Dopaminergic Regulation of Dynorphin Gene
Expression in the Basal Ganglia,"
Second International Conferences on Anatomical Sciences, Beijing,
China, 1992. "Molecular Mechanisms Underlying the Regulation of
Enkephalin and Catecholamine Synthesizing Enzymes in the
Adrenal Medulla,"
The fifth SCBA International Symposium and Workshops, Baltimore,
MD. 1993. "Molecular Mechanisms Underlying the Regulation of
Enkephalin and Catecholamine Synthesizing Enzymes in the
Adrenal Medulla,"
7th International Symposium on Chromaffin Cell Biology and
Pharmacology, Montebella, Canada, 1993. "Regulation of Opioid
Peptide Genes in the Adrenal Chromaffin Cells,"
The Neuroscience Symposium of the Mainland, Taiwan and Hong
Kong, Shanghai, China, 1993. "Regulation of the Proenkephalin
Gene in the Adrenal Medulla,"
The Second International Neuroscience Symposium - Gene
Expression in the Central Nervous System, Beijing, China, 1993.
"Regulation of the Opioid Peptide Genes in the Hippocampus,"
Symposium on Basic and Clinical Research of Opioids, Taipei,
Taiwan, 1994. "Molecular Mechanisms of Dopaminergic Modulation
of Opioid Peptides in the Basal Ganglia,"
Recent Advances on Biotechnology and Pharmaceutical
Development, Washington, DC, 1995. "Enkephalin Regulation in
Mixed Brain Cell Cultures - Possible Relevance to Reactive
Gliosis,"
Symposium on the Neurobiology of the Fos Family of Transcription
Factor, Bethesda, MD, 1996. "Roles of Long-Term Fra in the
Regulation of Opioid Peptides after Kainic Acid Treatment",
International Symposium on Advances on Neuroimmunology,
Beijing, 1997. “Roles of Endogenous Opioid Peptides in the
Regulation of Brain Neuroimmune Functions,”
International Conference Commemorating the 50th Anniversary of
the Korean Society of Pharmacology, Seoul, Korea, 1997.
“Interrelationship Between Opioid Peptides and Seizures in the
Hippocampus,”
International Symposium on Drug Abuse, Seoul, Korea, 1997.
“Roles of the Dopaminergic System in the Regulation of Opioid
Peptides in the Basal Ganglia,”
International Symposium on the Neuroimmune System, Taiwan,
1998. “Roles of the Brain Neuroimmune System in
Neurodegeneration,”
Satellite Symposium, Neuroscience Meeting, Miami Beach, FL,
1999. “Roles of the Brain Opioid System in the
Neuroimmune-mediated Neurodegendration",
Symposium, Neuroscience Society Meeting, New Orleans, LA, 2000.
“Cytokines and Neurodegeneration”,
Satellite Symposium, Neuroscience Society Meeting, New Orleans,
LA, 2000. “Roles of Nitric Oxide in Neurodegeneration”
Society of Neuro-immunopharmacology, Tampa, FL, 2002. “Role of
microglial activation in inflammation-related neurodegenerative
diseases”
Frontier in Neuroscience Symposium, Taiwan, 2003. “Role of
microglia in neurodegeneration”,
Recent Advances in Drug Therapy, Taiwan, 2003. “Novel
anti-inflammatory therapy for neurodegenerative diseases”
IWCN Meeting, Vancouver, Canada. 2003. “Inflammation and
Parkinson’s disease”
International Peptide Symposium, New York, 2003. “Potent
neuroprotective effect of ultra-low concentrations of neuropeptides
against LPS-induced dopaminergic neurons in midbrain neuron/glia
cultures”
8th International Parkinson’s Disease Symposium. New Orleans,
LA, 2003. “Inflammation-mediated Degeneration of Dopaminergic
Neurons: Mechanisms, Interventions and Relevance to Parkinson’s
Disease”.
Steering Committee Meeting for Collaborative Centers for
Parkinson’s Disease Environmental Research. NIEHS/NIH, 2003.
“Role of Inflammation in Parkinson’s Disease”
AMGEN Workshop, West Lake Village,
“Neuro-inflammation and Parkinson’s Disease”,
CA,
2004.
y” 7th International Conference in Neuroprotection. Monterey, CA,
2004. “Development of Novel Anti-inflammatory Therap
Environmental Factors in Neurodegenerative Disease Meeting,
NIEHS/NIH, 2004. “Neuropeptide mediation of microglia activation
and dopaminergic neurodegeneration: substance P vs dynorphin”
Asian Pacific Physiological Society Meeting, Taiwan, 2004. “Role of
microglia in inflammation-related neurodegeneration-mechanism,
therapeutic
interventions and relevance to Parkinson’s
disease”
16th International Congress on Parkinson’s disease and related
disorders, Berlin, Germany, 2005. “LPS-induced rodent Parkinson’s
disease model”
38th Winter Conference on Brain Research. Breckenridge, CO.2005.
“Why is Parkinsomn’s disease progressive?
38th Winter Conference on Brain Research. Breckenridge, CO.
2005. “Neuroinflammation: when, where, and how does it
contribute to degeneration?”
Inflammation and Parkinson's Disease Workshop. New York, NY
2005. “Microglia, inflammation and Parkinson’s disease”
Frontier in Neuroscience Research, Seoul, Korea, 2005. “Glial cells:
Key players in neurodegenerative diseases and prime targets for
therapy”
Annual Meeting of Neuropsyshitrics, National Health Research
Institute, Taiwan. 2005. “Microglia and inflammation-mediated
neurodegeneration: multiple triggers with a common mechanism.”
Asian Pacific Physiological Society Meeting, Taiwan, 2005. “Role of
microglia in inflammation-related neurodegeneration-mechanism,
therapeutic interventions and relevance to Parkinson’s disease”
NIDA Workshop, Bethesda, MD. 2006. “Glial cells: Key players in
neurodegenerative diseases and prime targets for therapy”
Annual Meeting of Neuroscience, Taiwan, 2006. “Microglia,
inflammation and Parkinson’s disease”
Symposium on aging and neurodegenerative diseases. Charlston,
South Carolina, 2006. “Glial cells: Key players in neurodegenerative
diseases and prime targets for therapy”.
Meetings of the Research Advisory Committee on Gulf War
Veteran’s Illness. Washington, D.C. 2006. “Microglial activation
following neurotoxic exposure: the self-propelling cycle of
neuroinflammation in neurodegenerative diseases”
Zunhi Medical University, 2006. “Microglia, inflammation and
Parkinson’s disease”
Workshop on Low-Dose of Naltrexone in Inflammatory-related
Diseases, NIH, Bethsda, MD. 2007“Anti-inflamamtory and
neuroprotective effects of morphinans: cellualr and morlecular
mechanism”
in International Society of Neurochemistry Meeting, Cancun,
Mexico, 2007. “Role of microglia in inflammation-related
neurodegeneration-mechanism, therapeutic interventions and
relevance to Parkinson’s disease”
XVII the WFN World Congress on Parkinson’s Disease and Related
Disordes. Amsterdam, the Netherlands, 2007. “Glial cells: Key
players in neurodegenerative diseases and prime targets for therapy”
Symposium on “Role of Environmental Factors in the Pathogenesis
of Parkiinson’s Disease” in CCPDER meeting. Asilomar Center,
Pacific Grove, CA 2007. “Microglia, inflammation and Parkinson’s
disease”
Udall Symposium on Parkinson’s disease. Pittsberg, PA, 2007. “Why
Parkinson’s disease is progressive”
International Neurotoxiciogy Meeting, San Antonio, TX, 2007.
“Role of inflammation in toxicant-induced injury in Parkinson’s
disease”,
Biotech Symposium, Taiwan, 2007. “Novel therapy for
inflammation-related diseases”
Symposium of Treatment of Parkinson’s Disease: Key Findings
during the Last 20 Years, Helsinki, Finland. 2008, “Glial cells: Key
players in neurodegenerative diseases and prime targets for therapy”
2008 Beijing Symposium on Aging and Neurodegeneration, Beijing,
China.
“Role
of
microglia
in
inflammation-related
neurodegeneration-mechanism, therapeutic interventions and
relevance to Parkinson’s disease”
Neural Prosthesis Workshop, Cleveland, OH 2008, “Role of
Neuroinflammation in the glia scar formation”.
Society on NeuroImmune Pharmacology Symposium, Wuhan, China
2009 “Why neurodegenerative diseases are progressive: uncontrolled
inflammation drives disease progression”.
First International Conference on Inflammation and Retinal Disease:
Complement Biology and Pathology, Crete, Greece, 2009. “Role of
microglia in inflammation-related neurodegeneration”.
International Society of Neurochemistry satellite meeting, Tappei,
Taiwan, 2009. “Inflammation-mediated Degeneration of
Dopaminergic Neurons: Mechanisms, Interventions and Relevance
to Parkinson’s Disease".
International Society of Neurochemistry satellite meeting, Seoul,
Korea, 2009. “Glial cells: Key players in neurodegenerative diseases
and prime targets for therapy”. workshop on Determining the need
and developing a strategy for a neurotoxicity testing. Vancouver
Canada, 2009. “Role of inflammation in toxicant-induced injury in
neurodegenerative disease”,
MENTORING
Trainee Awards by National Societies and NIEHS:
NIH FARE Award:
Raymond Chang 2000, Bin Liu, 2001, Bin Liu 2001, Liya Qin, 2002,
Liya Qin 2003, Huiming Gao, 2003. Michelle Block, 2005,
Tongguang Wang, 2005, Guorong Li, 2005. Pei
Zhong,
2005.Michelle Block, 2006. Xiaoming Hu, 2008.
Best Poster Award:
Wei Zhang 2004. Michelle Block 2005
Neuropeptide Meeting Travel Award:
Michelle Block 2005
BOOK CHAPTERS, CONFERENCE PROCEEDINGS, MONOGRAPHS
AND REVIEWS
1.
Poisner, A. M. and Hong, J. S.: Storage and release of
vasopressin from neurosecretory granules and the
neuropypophysis. In: Ceccarelli, B., Clementi, F., and
Medolesi, J. (eds.):
Cytopharmacology of Secretion.
Raven Press, New York, 1974, vol. 2, pp. 303-310.
2.
Guidotti, A., Gale, K., Hong, J. S., and Toffano, G.: Models
to study drug effect on the integrated function of GABAergic
peptidergic (substance P) and dopaminergic neurons. In:
Garattini, S., Pujol, J. F., and Samanin, R. (eds.):
Interactions Among Putative Neurotransmitters in the Brain.
Raven Press, New York, 1978, pp. 217-229.
3.
Yang, H. -Y., Hong, J. S., Fratta, W., and Costa, E.: Rat
brain enkephalins: Distribution and biosynthesis. In:
Costa, E. and Trabucchi, M. (eds.):
Advances in
Biochemical Psychopharmacology.
Raven Press, New
York, 1978, vol. 18, pp. 419-459.
4.
Costa, E., Fratta, W., Hong, J. S., Maroni, F., and Yang, -Y.
T.: Interactions between enkephalinergic and other neuronal
systems.
In: Costa, E. and Trabucchi, M. (eds.):
Advances in Biochemical Psychopharmacology. Raven
Press, New York, 1978, vol. 18, pp. 217-226.
5.
Hong, J. S., Yang, -Y. T., Gillin, J. C., Fratta, W., and Costa,
E.: Participation of Met5) enkephalin in the action of
antipsychotic drugs. In: Usdin, E. (ed.): Endorphins in
Mental Health Research.
MacMillan Press, London,
England, 1979, pp. 105-114.
6.
Yang, H., Hong, J. S., Fratta, W., and Costa, E.: An
approach to assess the dynamics of met5 enkephalin storage
in rat striatum. In: Usdin, E. (ed.): Endorphins in Mental
Health Research. MacMillan Press, London, England,
1979, pp. 235-241.
7.
Costa, E., Di Guillio, A., Fratta, W., Hong, J. S., and Yang,
-Y. T.:
Interactions of enkephalinergic and
catecholaminergic neurons in CNS and periphery. In:
Usdin, E., Kopin, I. J., and Barchas, J. D. (eds.):
Catecholamines: Basic and Clinical Frontiers. Pergamon
Press, Oxford, 1979, pp. 1020-1025.
8.
Yang, H. -Y. T., Hong, J. S., and Costa, E.: The search for
proenkephalin: Experimental tools and status of art. In:
Albertini, A., Da Prada, M., and Peskar, B.A. (eds.):
Radioimmunoassay of Drugs and Hormones in
Cardiovascular Medicine. Biomedical Press, 1979, pp.
309-318.
9.
Gillin, J. C., Hong, J. S., Yang, H. -Y. T., and Costa, E.:
Does lithium act by selectivity affecting a brain enkephalin
system? In: Copper, T. B., Gershon, S., Kline, N. S., and
Schou, M. (eds.): Lithium-Controversies and Unresolved
Issues. Excerpta Medica, 1979, pp. 781-788.
10.
Hong, J. S., Yang, H. -Y. T., Gillin, J. C. and Costa, E.:
Effects of long term administration of antipsychotic drugs on
enkephalinergic neurons. In: Cattabeni, F., et al. (eds):
Advances in Biochemical Psychopharmacology. Raven
Press, 1980, vol. 24, pp. 223-232.
11.
Hong, J. S., Wood, P., Gillin, J. C., Yang, H. -Y. T. and Costa,
E.:
Recurrent
convulsions
and
hippocampal
(Met5)-enkephalin content. In: Costa, E. and Trabucchi, M.
(eds.): Advances in Biochemical Psychopharmacology.
Raven Press, 1980, vol. 22, pp. 385-398.
12.
Costa, E., Hong, J. S. and Yang, H. -Y. T.: Are enkephalins
brain putative neurotransmitters? In: Vizi, E. S. (ed.):
Modulation of Neurochemical Transmission. Pergamon
Press, 1980, pp. 57-74.
13.
Rosecrans, J. A., Hong, J. S. and Tilson, H. A.: Effects of
conditioned
analgesia
(autoanalgesia)
on
the
pituitary-adrenal function and brain neuropeptides in rats
selected for differences in activity. In: Costa, E. and
Trabucchi, M. (eds.):
Regulatory Peptides: From
Molecular Biology to Function. Raven Press, New York,
1982, pp. 151-156.
14.
Hong, J. S.: Effects of administration of psychoactive drugs
on brain neuropeptide systems. In: Namba, M. and Kaiya,
H. (eds.): Psychobiology of Schizophrenia. Pergamon
Press, New York, 1982, pp. 155-163.
15.
Kleinman, J. E., Karoum, F., Rosenblatt, J. E., Gillin, J. C.,
Hong, J. S., Bridge, T. P., Zaleman, S., Storch, F., del
Carman, R., and Wyatt, R. J.: Postmortem neurochemical
studies in chronic schizophrenia. In: Usdin, E. and Hanin, I.
(eds.): Biological Markers in Psychiatry and Neurology.
Pergamon Press, New York, 1982, pp. 67-76.
16.
Kleinman, J. E., Karoum, F., Rosenblatt, J., Gillin, J. C.,
Hong, J. S., Bridge, P., Zaleman, S., Storch, F., del Carman,
R., and Wyatt, R. J.: Catecholamine and peptides in
postmortem schizophrenic brains. In: Perb, C., Jansson,
B. and Struwe, G. (eds.): Biological Psychiatry 1981
Developments in Psychiatry.
Vol. 5, Elsevier,
North-Holland, Amsterdam, 1982, pp. 711-714.
17.
Lamartiniere, C. A., Hong, J. S., and Mason, G. A.:
Endocrine factors involved in sexual differentiation of
brain-pituitary-liver axis.
In:
Neuropeptides,
Neurotransmitters and Regulation of Endocrine Processes.
Ed. by Endroczi, Akademiai Kiada, Budapest, 1983, pp.
107-115.
18.
Hong, J. S., Yoshikawa, K., and Hendren, W.: Measurement
of enkephalins and endorphin related peptides in biological
tissues and fluids. In: Conn, M. (ed.): Methods of
Enzymology.
Academic Press, New York, 1983, pp.
547-564.
19.
Hong, J. S., Yoshikawa, K., and Lamartiniere, C. A.:
Hormonal regulation of pituitary endorphin systems. In:
Hanin, I. (ed.): Dynamics of Neurotransmitter Function.
Raven Press, New York, 1984, pp. 149-157.
20.
McGinty, J. F., Kanamatsu, T., Obie, J., and Hong, J. S.:
Modulation of opioid peptide metabolism by seizures:
differentiation of opioid subclasses.
NIDA Research
Monograph Series, vol. 71, 1986, pp. 89-101.
21.
Viveros, O. H., Diliberto, E. J. Jr., Hong, J. S., Kizer, J. S.,
Unsworth, C. D., and Kanamatsu, T.: The regulation of
enkephalin levels in adrenomedullary cells and its regulation
to chromaffin vesicle biogenesis and functional plasticity.
Ann. N.Y. Acad. Sci. 493: 324-341, 1987.
22.
Hong, J. S., Grimes, L., Kanamatsu, T., and McGinty, J. F.:
Kainic acid as a tool to study the regulation and function of
opioid peptides in the hippocampus. Toxicology 46: 1987,
141-157.
23.
Tilson, H. A., Hong, J. S., Gerhart, J. M., and Walsh, T. J.:
Animal models in neurotoxicology: The neurobehavioral
effects of chlordecone (KeponeR). In: Advances in
Behavioral Pharmacology, Vol. 6, 1987, pp. 249-273.
24.
Viveros, O. H., Unsworth, C. D., Kanamatsu, T., Hong, J. S.,
and Diliberto Jr., E. J.:
Nicotinic regulation of
adrenomedullary opioid peptide synthesis and secretion: A
model to study monoamine neuropeptide cotransmission.
In: Martin, W. R., VanLoon, N. P., Iwamoto, E. T., and Davis,
L. (eds.): Proceedings of theInternational Symposium on
Tobacco Smoking and Health: A Neurological Approach,
1987, pp. 341-356.
25.
McGinty, J. F., Kanamatsu, T., Morton, J. D., Frederickson,
C. J., and Hong, J. S.: Seizure-induced alterations of
opioid peptide and zinc metabolism. In: Nutritional
Modulation of Neural Function. Academic Press, 1988, pp.
271-287.
26.
Hong, J. S., Grimes, L., Kanamatsu, T., Obie, J., and
Mitchell, C. L.: Seizure-induced alterations in the
metabolism of hippocampal opioid peptides suggest opioid
modulation of seizure-related behaviors. NIDA Research
Monograph, vol. 82, 1988, pp. 48-66.
27.
Tilson, H. A., Zhao, D., Peterson, N. J., Nanry K., and Hong,
J. S.: Behavioral and neurological effects of aspartame. In:
Wurtman, R. and Ritter-Walker, E (eds.): Dietary
Phenylalanine and Brain Function. Birkhauser, Boston, 1988,
pp. 107-115.
28.
Toretella, F. C., Long, J. B., Hong, J. S., and Holaday, J. W.:
Modulation of endogenous opioid systems by
electroconvulsive shock. In: Convulsive Therapy, 5:
261-273, 1989.
29.
Douglass, J., Iadarola, M., Hong, J. S., Garrett, J. E., and
McMurray, C. T.: Transcriptional regulation of the rat
prodynorphin gene. NIDA Research Monograph, 111, pp.
132-149, 1991.
30.
Hong, J. S.: Hippocampal opioid peptides and seizures.
In: Ribak, C. E., Gall, C. and Mody, I. (eds.) The Dentate
Gyrus and Its Role in Seizures, pp. 187-196, 1992.
31.
Hong, J. S. and Stachowiak, M.: Regulation of enkephalin
and catechlamine synthesizing enzymes in the adrenal
medulla.
In: L.F. Tseng (ed.):
Pharmacology. pp. 151-168, 1995.
Opioid
peptide
32.
Bing, G., Wilson, McMillian, M.K., Feng, Z., Qi, Q., Kim,
H.C., Wang, W., Jensen, K. and Hong, J. S.: Long-term
expression of proenkephalin and prodynorphin in the rat
brain after systemic administration of kainic acid--An in situ
hybridization study. In : G. Fiskum(ed.): Neurodegenerative
Diseases, pp. 9-18, 1997.
33.
Sundar, K.S., Kamaraju, L.S., Dingfelder, J., McMahon, J.,
Bitonta, R.A., Gollapud, S., Wilson, W.H., Kong, L.Y., Hong,
J. S., and Lee, J.E.: Endogenous opioids and HIV infection.
From AIDS, Drug Abuse and the Neuroimmune Axis. Ed. by
Fridman et al., Plenum publisher (in press).
34.
Pennypacker, K and Hong, J. S.: Fos-Related Antigens. In:
T.E. Creghyton (ed):
The Encyclopedia of Molecular
Medicine. Wiley pp 1319-1320, 2002.
35.
Jeohn, G.H., Cooper, C.L., Jang, K-J., Kim, H-C. and Hong,
J. S.: Go6976 protects
mesencephalic
neurons from LPS-elicited death by inhibiting p38 MAP
kinase phosphorylation. Ann. N.Y. Acad. Sci. pp 347-359,
2002.
36.
Cooper, C., Jeohn, G., Tobia, P. and Hong, J. S.: Serum
dependent of LPS-induced neurotoxicity in rat cortical
neurons. Ann. N.Y. Acad. Sci. 2002.
37.
Liu, B., Gao, K., Jeohn, G., Cooper, C. and Hong J. S.: Roles
of nitric oxide in inflammation-mediated neurodegeneration.
Ann. N.Y. Acad. Sci. pp306-317, 2002.
38.
Jeohn, G.H., Cooper, C., Wilson, B., Chang, R., Jang, K.,
Kim, H. and Hong, J. S.: p38 kinase is involved in
LPS-induced dopaminergic neuronal cell death in rat
mescenphalic neuro-glia cultures. Ann. N.Y. Acad. Sci.
pp332-346, 2002.
39.
Liu, B. and Hong, J. S. Primary rat mesencephalic
neuron-glia, enriched-neuron, enriched-microglia and
enriched-astroglia cultures. Methods Mol. Med. 79: 387-395,
2003.
40.
Liu. B.and Hong, J. S. Neuroprotective effect of naloxone in
inflammation-mediated
dopamine
neurodegeneration:
dissociation from the involvement of opioid receptors.
Methods Mol. Med. 79:43-54, 2003.
41
Zhang, W., Hong, J. S. and Block, M.: Neuroprotective
effects
of
morphinans
on
inflammation-related
neurodegenerative
diseases.
Critical
Review
in
Neurobiology 16: 271-302, 2004.
42
Gao, H. and Hong, J. S.: On the mechanism of
rotenone-induced neurotoxicity-role of microglia. Toxicol.
App. Pharmac. (in review)
43
Qin, L, Liu, Y, Qian, X. Hong, J.S. and Block, M.:
Microglial NADPH oxidase mediates leucine enkephalin in
dopaminergic neuroprotection. Ann N.Y. Acad.Sci. 1953:
107-120, 2005.
44
Block, M. and Hong, J.S.: Microglia and
inflammation-mediated neurodegeneration: multiple triggers
with a common mechanism. Progress in Neurobiology 76:
77-98, 2005.
45.
Qian, L. Hong J.S. and Flood, P.: Role of Microglia in
Inflammation-medicated Degeneration of Dopaminergic
Neurons: Neuroprotective Effect of Interleukin(IL)-10. In
Proceeddings of 16 th International Congress of Parkinson’s
Disease, 2005.
46.
Hong, J.S.: Role of inflammation in the
pathogenesis of Parkinson's disease: models, mechanisms,
and therapeutic interventions. Ann N Y Acad.Sci.1053:151,
2005.
47.
Berman JW, Carson MJ, Chang L, Cox BM, Fox HS,
Gonzalez RG, Hanson GR, Hauser KF, Ho WZ, Hong JS et
al. NeuroAIDS, drug abuse, and inflammation: building
collaborative research activities. J Neuroimmune Pharmacol.
1:351-99, 2006.